Boston Scientific Launches Third-Generation Platinum Chromium Drug-Eluting Stent
/* 468x60, */
Boston Scientific Corporation (NYSE: BSX) announced the set off of the platinum chromium TAXUS(R) Element(TM) Paclitaxel-Eluting Coronary Stent Step in take markets worldwide. The TAXUS Component Stent features a current platinum chromium alloy engineered specifically for coronary stent applications and represents the Company's third-generation drug-eluting stent (DES) technology.
The Element Stent series consists of three distinct versions: the Paclitaxel-Eluting TAXUS Element Stent, the Everolimus-Eluting PROMUS(R) Element(TM) Stent and the bare-metal Element Stent(1). All three versions of the Element Stent are built on the original platinum chromium platform and are designed to cater interventional cardiologists improved performance in treating patients with entangled coronary artery disease. The Corporation is anticipating CE Speck approval for both the TAXUS Element Stent and the PROMUS Element Stent Systems in the fourth quarter of this year.
The platinum chromium alloy used in the Element Stent Course was engineered specifically for coronary stenting, delivering both vigour and flexibility. The Element Stent System platform further features a new stent architecture with thinner struts, increased flexibility and a lower profile, designed to emend radial strength, recoil and angiographic visibility. Deliverability to complicated lesions is besides enhanced through the incorporation of a just out highly deliverable dilatation catheter technology.
"It is expressly big-league to hog a scale of options when selecting the exactly treatment for patients with challenging coronary lesions," said Dean J. Kereiakes, M.D., Medical Director at The Christ Hospital Heart and Vascular Centre and The Lindner Check Center in Cincinnati, Ohio and a principal investigator for the TAXUS PERSEUS clinical evaluation evaluating the TAXUS Element Stent. "The Element Stent series is intended to accommodate a full range of DES solutions for interventional cardiologists, giving them the option to treat patients with a paclitaxel, everolimus or bare-metal stent. In my experience, the TAXUS Element Stent is a highly deliverable and conformable platform that has the potential to simplify complex procedures and improve outcomes."
"Our platinum chromium Element Stent series represents a meaning leap forward in drug-eluting stent innovation," said David McFaul, Boston Scientific Senior Vise President, International. "This breakthrough technology combines a new alloy designed for coronary stenting, an innovative stent draw and a latest delivery system."
The TAXUS Element Stent Operation is currently being studied in the PERSEUS clinical proof program, which compares the TAXUS Element Stent System to the TAXUS(R) Express2(R) Stent System. The program includes the PERSEUS Workhorse and the PERSEUS Small Vessel arms. Both own finished recruiting patients and are estimated to be completed by the end of the year. The PROMUS Element Stent Action is currently life studied in the PLATINUM clinical research program, which compares the PROMUS Element Stent Method to the PROMUS(R) Stent System, and is actively enrolling patients in the U.S., Europe and Japan.
While the Element Stent platform represents Boston Scientific's third-generation DES technology, the Company's fourth-generation DES is currently under development. Initial clinical material were presented at the Transcatheter Cardiovascular Therapeutics scientific symposium in 2008; global pivotal trials are expected to begin in 2010. This DES employs the Labcoat technology, which has an ultra thin biodegradable abluminal polymer that delivers a very low potion of paclitaxel to the wall of the treated vessel, and no polymer or narcotic on the inner surface of the stent. Integrating the Element Stent architecture and a platinum chromium alloy with an optimized drug release, the "Labcoat Element" Stent(2) is designed to deliver a competent combination of procedural and clinical performance.
In the United States, the TAXUS Element Stent and PROMUS Element Stent are investigational devices and are community by applicable code to investigational avail alone and are not available for sale.
The PROMUS Stent is a private-labeled Xience V(R) Everolimus-Eluting Coronary Stent System manufactured by Abbott and distributed by Boston Scientific. Xience V is a trademark of the Abbott Laboratories group of companies.
Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a wide range of interventional medical specialties.
Source: Boston Scientific Association
/* 468x60, */
Last relative articles:
- Use Of Statins Increases The Risk Of Developing Type 2 Diabetes But Reduces Coronary Events
- Heart Failure Worse When Right Ventricle Goes Bad
- Cooling Inflammation For Healthier Arteries
- Experts Identify Why Women And African Americans Face A Greater Risk Of Dying From Heart Disease Than White Men And What Can Be Done About It
- New Book Helps Pharmacists Play Larger Role In Heart Health
- Novel Screening Technique Identifies New Effects Of Approved Drugs For Cardiovascular Disease
- Compound Shows Promise Against Intractable Heart Failure
- Researchers Find Air Pollution Linked To Progression Of Atherosclerosis
- Heart-Assist Device Helped Ready 16-Year-Old For Successful Surgery
- Seven Signs That May Warn Of A Rare Heart Condition
stent, element stent, stent boston, stent system, chromium stent, coronary stent, stent architecture, stent series, stent promus, stent features